MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α

Abstract

BackgroundEndometrial carcinoma (EC) is one of the most lethal gynecologic cancers. Patients frequently have regional or distant metastasis at diagnosis. MicroRNAs are small non-coding RNAs that participate in numerous biological processes. Recent studies have demonstrated that miR-505 is associated with several types of cancer; however, the expression and function of miR-505 have not been investigated in EC.MethodsmiR-505 expression in normal endometrial tissue, endometrial carcinomas were quantified by Quantitative reverse transcription PCR. The endometrial carcinoma cell lines HEC-1B and Ishikawa were each transfected with miR-505 or scrambled mimics, after which cell phenotype and expression of relevant molecules were assayed. Dual-luciferase reporter assay and a xenograft mouse model were used to examine miR-505 and its target gene TGF-α.ResultsRT-PCR results demonstrated that miR-505 was significantly downregulated in human EC tissues compared to normal endometrial tissues. Besides, miR-505 expression was negatively associated with FIGO stage (stage I-II vs. III-IV), and lymph node metastasis (negative vs. positive). In vitro, overexpression of miR-505 significantly suppressed EC cell proliferation, increased apoptosis and reduced migratory and invasive activity. A miR-505 binding site was identified in the 3′ untranslated region of TGF-α mRNA (TGFA) using miRNA target-detecting software; a dual luciferase reporter assay confirmed that miR-505 directly targets and regulates TGFA. RT-PCR and Western-blotting results indicated that overexpressing miR-505 reduced the expression of TGF-α and the TGF-α-regulated proteins MMP2, MMP9, CDK2, while induced Bax and cleaved-PARP expression in EC cells. In vivo, overexpression of miR-505 reduced the tumorigenicity and inhibited the growth of xenograft tumors in a mouse model of EC.ConclusionsTaken together, this study demonstrates that miR-505 acts as tumor suppressor in EC by regulating TGF-α.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-016-0496-4) contains supplementary material, which is available to authorized users.

miR-27a attenuates adipogenesis and promotes osteogenesis in steroid-induced rat BMSCs by targeting PPARγ and GREM1

“…Since the miRNAs degrade in transiently transfected cells over time, 50 nM miRNAs are usually adopted as a working concentration, which can lead to an overexpression of the miRNA at the early stage after transfection. However, this method is well accepted by many researchers in miRNA study since it can detect miRNA function with more convenience and less expense434445. Here, we found that miR-27a up-regulation enhanced osteogenic differentiation and suppressed adipogenic differentiation by inhibiting PPARγ and GREM1 in steroid-induced rat BMSCs.…”

MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8

“…That might because the target genes of miR‐505 were largely involving in inhabitation of tumour progression and highly expressed miR‐505 could repress the expression of anti‐oncogenes resulting in the promotion of tumour. It has been reported that overexpression of miR‐505 could inhibit proliferation, induce apoptosis and reduce the tumorigenicity of endometrial cancer cells in vitro . Lu et al .…”

MiR‐505 promotes M2 polarization in choroidal neovascularization model mice by targeting transmembrane protein 229B

“…The kaleidoscopic biological functions of miRNAs are increasingly acknowledged in the development of various human diseases, among which miR‐505 was considered as a tumour suppressor in several malignancies. For example, it was confirmed that the tumour suppressor function of miR‐505 in endometrial cancer by targeting TGF‐α . In hepatoma cells, miR‐505 suppressed proliferation and invasion by directly targeting high‐mobility group box 1.…”